Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 998.35 INR 0.36% Market Closed
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Operating Margin
Divi's Laboratories Ltd

23.7%
Current
31%
Average
2.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.7%
=
Operating Profit
19.4B
/
Revenue
81.9B

Operating Margin Across Competitors

Country IN
Market Cap 1.6T INR
Operating Margin
24%
Country US
Market Cap 1.3T USD
Operating Margin
14%
Country US
Market Cap 196.3B USD
Operating Margin
17%
Country US
Market Cap 170.3B USD
Operating Margin
21%
Country KR
Market Cap 66.5T KRW
Operating Margin
31%
Country CH
Market Cap 37.6B CHF
Operating Margin
13%
Country US
Market Cap 38.5B USD
Operating Margin
25%
Country US
Market Cap 36.7B USD
Operating Margin
14%
Country US
Market Cap 26.4B USD
Operating Margin
28%
Country US
Market Cap 23B USD
Operating Margin
20%
Country US
Market Cap 22.3B USD
Operating Margin
8%
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. is a prominent player in the pharmaceutical industry, primarily known for its role as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1990, the company has established a robust reputation for its high-quality products and commitment to research and development. With an extensive product portfolio that serves a multitude of therapeutic areas, including pain management, oncology, and cardiovascular treatments, Divi's has positioned itself as a trusted partner to both domestic and global pharmaceutical companies. The company's state-of-the-art manufacturing facilities, compliant with international regulatory standards, ensure that it meets the growing demand for cost-effective and high-quality APIs, which is increasingly vital as the world turns to generics and specialty medicines. For investors, Divi's Laboratories presents a compelling opportunity anchored in its sustainable growth trajectory and financial resilience. Over the years, the company has demonstrated strong revenue growth and healthy profit margins, reflecting its operational efficiency and strategic focus on innovation. With a diversified customer base across more than 95 countries, the company is well-positioned to capitalize on emerging market trends and the ongoing expansion in global healthcare requirements. As healthcare systems evolve and the demand for affordable pharmaceuticals surges, Divi’s commitment to excellence and innovation keeps it at the forefront of the industry, making it an attractive investment for those looking to align with a company that not only generates value but also significantly contributes to global health outcomes.

DIVISLAB Intrinsic Value
2 897.57 INR
Overvaluation 52%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
23.7%
=
Operating Profit
19.4B
/
Revenue
81.9B
What is the Operating Margin of Divi's Laboratories Ltd?

Based on Divi's Laboratories Ltd's most recent financial statements, the company has Operating Margin of 23.7%.